Amarantus Announces Positive MANF Ocular Toxicology Data

New Post Public Reply Private Reply Replies (0) Message Board
News Desk 2018
Amarantus Announces Positive MANF Ocular Toxicology Data

SAN FRANCISCO and GENEVA, Sept. 9, 2014 (GLOBE NEWSWIRE) -- Amarantus Bioscience Holdings, Inc. (OTCQB:AMBS),  a biotechnology company focused on the development of diagnostic and therapeutic interventions for Alzheimer's disease, Parkinson's disease and orphan ophthalmological disorders, today announced positive 15-day non-GLP toxicology data for a single intravitreal administration of MANF in an ocular safety animal model, relevant to MANF's development in ocular diseases, including orphan indications such as Retinitis Pigmentosa. The intravitreal method of administration was chosen because it is the delivery method expected for human application of MANF. The experiments were conducted at a leading ophthalmology contract research laboratory in France.

"We are pleased to see continued progress in our orphan program for MANF in ophthalmological diseases," said Gerald E. Commissiong, President & CEO of Amarantus. "The results seen in this ocular tolerance study are encouraging for an initial clinical focus on MANF in orphan ocular diseases. This data will support the preparation of our orphan drug designation application with the FDA for MANF in one or more ocular disorders in the fourth quarter, including Retinitis Pigmentosa."

The aim of this study was to evaluate the ocular tolerance of MANF after a single intravitreal administration in pigmented rabbits over a 15 day period at dosing levels expected to be above therapeutically relevant dosing levels in human. Ten female pigmented rabbits were divided in two groups of five animals each, corresponding to treatment with MANF and treatment with vehicle (control). MANF and the vehicle were dosed by intravitreal injection in the right eye once, on Day 1. Slit-lamp examinations on four days during the 15-day follow-up period were complemented with a histopathology evaluation of the treated eyes on day 15. There were no treatment or administration-related effects on body weight, clinical observations or ophthalmic examinations. No pathological findings related to treatment were found in any of the eyes observed during histopathology evaluation. The report from the study concluded that a single intravitreal administration of MANF in pigmented rabbits was macroscopically and microscopically very well tolerated.

About Retinitis Pigmentosa

Retinitis Pigmentosa (RP) refers to a group of inherited diseases causing retinal degeneration. The cell-rich retina lines the back inside wall of the eye and is responsible for capturing images from the visual field. People with RP experience a gradual decline in their vision because photoreceptor cells (rods and cones) die. Symptoms include a progressive degeneration of peripheral and night vision as well as the degeneration in color perception and central vision; night blindness is one of the earliest and most frequent symptoms of RP. RP is typically diagnosed in adolescents and young adults. The rate of progression and degree of visual loss varies from person to person. Most people with RP are legally blind by age 40. There are approximately 100,000 patients in the United States, 100,000 patients in Europe and 50,000 patients in Japan diagnosed with RP, qualifying is as an orphan indication. There are currently no approved treatments in the market. It is estimated the RP is a multi-billion dollar market opportunity.

About Mesencephalic-Astrocyte-derived Neurotrophic Factor (MANF)

MANF (Mesencephalic-Astrocyte-derived Neurotrophic Factor) is believed to have broad potential because it is a naturally-occurring protein produced by the body for the purpose of reducing and preventing apoptosis (cell death) in response to injury or disease, via the unfolded protein response of the endoplasmic reticulum. By manufacturing MANF and administering it to the body, Amarantus is seeking to use a regenerative medicine approach to assist the body with higher quantities of MANF when needed. Amarantus is the front-runner and primary holder of intellectual property (IP) around MANF, and is initially focusing on the development of MANF-based protein therapeutics. MANF's current lead indication is Retinitis Pigmentosa, and other applications including Parkinson's disease, Alzheimer's disease and Wolfram's Syndrome. Additional applications for MANF may include Traumatic Brain Injury (TBI), myocardial infarction, antibiotic-induced ototoxicity and certain other rare orphan diseases currently under evaluation.

About Amarantus BioScience Holdings, Inc.

Amarantus BioScience Holdings (AMBS) is a biotechnology company developing treatments and diagnostics for diseases associated with neurodegeneration and protein misfolding-related apoptosis. AMBS has licensed Eltoprazine ("Eltoprazine"), a phase 2b ready small molecule indicated for Parkinson's Levodopa induced dyskinesia and Adult ADHD. AMBS has an exclusive worldwide license to the Lymphocyte Proliferation test ("LymPro Test(R)") for Alzheimer's disease and owns the intellectual property rights to a therapeutic protein known as Mesencephalic-Astrocyte-derived Neurotrophic Factor ("MANF") and is developing MANF-based products as treatments for brain disorders. AMBS also owns intellectual property for the diagnosis of Parkinson's disease ("NuroPro") and the discovery of neurotrophic factors ("PhenoGuard"). Amarantus operations are located at Janssen Labs @QB3 in San Francisco, CA. For further information please visit www.Amarantus.com , or connect with the Company on Facebook , LinkedIn , Twitter and Google+ .

Certain statements, other than purely historical information, including estimates, projections, statements relating to our business plans, objectives, and expected operating results, and the assumptions upon which those statements are based, are forward-looking statements." These forward-looking statements generally are identified by the words believes," project," expects," anticipates," estimates," intends," strategy," plan," may," will," would," will be," will continue," will likely result," and similar expressions. Forward-looking statements are based on current expectations and assumptions that are subject to risks and uncertainties which may cause actual results to differ materially from the forward-looking statements. Our ability to predict results or the actual effect of future plans or strategies is inherently uncertain. Factors which could have a material adverse effect on our operations and future prospects on a consolidated basis include, but are not limited to: changes in economic conditions, legislative/regulatory changes, availability of capital, interest rates, competition, and generally accepted accounting principles. These risks and uncertainties should also be considered in evaluating forward-looking statements and undue reliance should not be placed on such statements.

Amarantus Bioscience Holdings, Inc. Aimee Boutcher, Investor Relations 408.737.2734 x 101 Planet Communications Deanne Eagle, Media Contact (917) 837-5866

Scroll down for more posts ▼

Top 10 Most Recent News Articles

iHeartMedia Faces 65% Drop: Fraud Investigation Launched

Updated Category News Views 40

Trouble Tunes for iHeartMedia Investors Alright folks, here's the skinny on iHeartMedia, Inc. These days, it's like everyone's out for a piece of iHeart, and not in the way you'd wanna see—unless you're SBS Law, those shareholder rights hotshots diving into another pond of legal ripples. Seems a heap of head-scratching's going down on their version of transparency with...

Continue Reading
Disney+ Teams Up with Tiff's: Blue Cookie Debut

Updated Category News Views 52

A Sweet Collaboration on the Horizon If somebody had told me that cookies could conjure up excitement equivalent to a TV show's new season, I'd have laughed. But here we are—Disney+ and Tiff's Treats are cooking up a storm with blue chocolate chip cookies to celebrate 'Percy Jackson and the Olympians' Season 3 premiere. The Cookie That Packs a Punch Forget ordinary...

Continue Reading
Crocs to Present at Key Industry Conferences

Updated Category News Views 48

Crocs Set to Step into the Spotlight Alright, if there's one thing about Crocs, Inc. (NASDAQ: CROX) that never fails to surprise, it's how they constantly keep everyone on their toes. The iconic casual footwear brand with its whimsical, love-it-or-hate-it reputation is strapping in for not one but two hefty conferences. They've circled November 19 and December 1, 2026, on...

Continue Reading
Chicken Production Rises Amid Meat Market Shifts

Updated Category News Views 41

Protein Markets Scramble: Chicken Production Climbs Here’s a tasty tidbit that might just have investors reeling: the USDA says chicken production will be cruising on the up, whereas beef is taking a bit of a backseat. Yep, the big birds are flying higher, and the cows, well, they're just mooing a little softer. And what's that mean for big players like Tyson...

Continue Reading
Caregiving's Financial Impact on Women: Insights from Cinergy

Updated Category News Views 96

Women Caregivers Face Financial Crossroads When it comes down to it, caregiving is one heck of a responsibility, particularly for women. It's about the sacrifices they make, not just in time but in financial security, too. Step away from a job to care for someone, and it's a dicey game you're playing with future income. The Cost of Generosity: Financial Impacts Cindy...

Continue Reading
Flagship's £100M London Move to Ignite AI Ventures

Updated Category News Views 242

London Calling: Flagship's New Venture Flagship Pioneering, the brain behind bustling biotech ventures like Moderna, is planting its flag in London. They're launching Flagship Origination Lab, U.K., their first real gig outside good ol' Cambridge, Massachusetts. They're diving in headfirst, sprinkling a whopping £100 million to brew up AI-native platform companies. And...

Continue Reading
Lennar Faces Legal Heat Over Alleged Misleading Statements

Updated Category News Views 78

Rumbling Legal Drama with Lennar Corporation Every trader knows the uneasy feeling when a stock you're eyeing takes a surprising nosedive on some legal muck coming out of the woodwork. Well, it's Lennar Corporation's turn in the spotlight for all the wrong reasons. They're getting slapped with a class action lawsuit by investors claiming the company pulled a fast one...

Continue Reading
SahajMobile's $25M Boost: Impact on Bangladesh Market

Updated Category News Views 98

Untapped Digital Frontier in Bangladesh There's an undeniable buzz around SahajMobile's recent $25 million credit facility, and it's one worth dissecting. This shot of capital, lined up with ALMA as part of SahajMobile’s Series A gamble, is setting the stage for a real shuffle in Bangladesh's digital landscape. Plugging into a Market Gap Ever since it hit the ground...

Continue Reading
Panasonic Showcases Rugged Tech at NATO Edge 26

Updated Category News Views 41

Panasonic Heads to Turkey with Tactical Tech Panasonic's got its sights set on proving a point at NATO Edge 26, busting out its TOUGHBOOK line and showing just how these rugged laptops aren't just tough, but also strategically essential. From November 17th through 19th, down in Turkey, these devices are taking the spotlight as they embrace the operational challenges of...

Continue Reading
Mars Moves on Cash Tender Offers for Seniors' Notes

Updated Category News Views 104

A Strategic Financial Maneuver or a Casual Gambit? Okay, what’s Mars up to now, you ask? Here we go with this. The behemoth behind some of your favorite snacks and pet indulgences is making waves—not with candy, but with cash. Mars, Incorporated is rolling out tender offers to buy back a substantial chunk of its Senior Notes for $2 billion in cold, hard cash. When a...

Continue Reading

Top 5 Most Recently Viewed Articles

Jefferies Reports Optimism for Vertiv's Future Growth Potential

Updated Category News Views 95

Jefferies Boosts Vertiv Holdings Co. Stock Outlook Recently, Vertiv Holdings Co. (NYSE: VRT), known for its vital role in digital infrastructure and continuity solutions, captured attention with its promising assessment by Jefferies, a prominent financial firm. Jefferies has initiated coverage on Vertiv with a favorable Buy rating, establishing an ambitious price target...

Continue Reading
BioAdaptives: A New Era Ahead Post-Reverse Stock Split

Updated Category News Views 212

Transforming BioAdaptives for a Brighter Future In a recent update, BioAdaptives, Inc. has provided shareholders with insights regarding a key decision that impacts its future direction. After experiencing significant growth in the number of its outstanding shares without corresponding revenue growth, management recognizes the urgent need for a strategic pivot. The...

Continue Reading
Explore Spacious Model Homes at The Timbers for Active Adults

Updated Category News Views 49

Introducing The Timbers at Everlands Lennar, a prominent name in homebuilding, is excited to announce the grand opening of new model homes at The Timbers at Everlands, an innovative community tailored for active adults. These stunning homes offer three distinct styles as well as numerous amenities that cater to comfort and lively living. A Vibrant Community for Active...

Continue Reading
Emerging Innovations in the Tire Technologies Market

Updated Category News Views 410

The Evolution of Tire Technologies in a New Era As electric vehicles (EVs) transform the world of transportation, the tire sector is witnessing a crucial revolution. Gone are the days when tires were merely black rubber circles; today, they are integral to vehicle performance, providing not just grip but also intelligence. With innovations in tire design and technology,...

Continue Reading
Streamlined Emergency Cash Options: Wizzay's New Features

Updated Category News Views 209

Introducing Wizzay's 1-Hour Payday Loans In today's fast-paced world, unexpected expenses can arise at any moment. Wizzay has rolled out a groundbreaking solution for those looking for quick access to funds: 1-hour payday loans that don't involve hard credit checks. This new program is tailored for individuals who require immediate financial assistance, with many...

Continue Reading